Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

277
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
277
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

248
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
248
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

241
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
241
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

315
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
315
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

250
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
250

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is It Time to Focus Efforts to Better Understand Group 3 Pulmonary Hypertension in Patients With Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis?

Chest·2026
Same author

Insurance and Treatment Patterns in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.

Annals of the American Thoracic Society·2026
Same author

Managing a Critically Ill Patient With Pulmonary Arterial Hypertension.

Chest·2026
Same author

The Natural History of Chronic Lung Allograft Dysfunction in Single and Bilateral Orthotopic Lung Transplant Recipients.

Transplantation·2026
Same author

Corrigendum to 'The landscape of referrals for lung transplantation in pulmonary arterial hypertension: A report from the Pulmonary Hypertension Association Registry'[J Heart Lung Transplant, 45 (2026) 125-136].

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Private Equity and the Corporatization of Health Care: Implications for Pulmonary, Critical Care, and Sleep Medicine.

Annals of the American Thoracic Society·2026

Related Experiment Video

Updated: Sep 4, 2025

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.1K

Methamphetamine-associated pulmonary arterial hypertension.

Nicholas A Kolaitis1, Rajan Saggar2, Teresa De Marco1

  • 1Department of Medicine, University of California, San Francisco School of Medicine, San Francisco.

Current Opinion in Pulmonary Medicine
|July 15, 2022
PubMed
Summary

Methamphetamine use definitively causes pulmonary arterial hypertension (PAH). Patients with methamphetamine-associated PAH experience worse health outcomes and survival compared to those with idiopathic PAH.

More Related Videos

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

350

Related Experiment Videos

Last Updated: Sep 4, 2025

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.1K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

350

Area of Science:

  • Cardiology
  • Pulmonology
  • Toxicology

Background:

  • Global rise in methamphetamine use leads to significant drug toxicities.
  • Pulmonary arterial hypertension (PAH) is a recognized toxicity of chronic methamphetamine abuse.
  • The sixth World Symposium on Pulmonary Hypertension now classifies methamphetamine use as a definitive cause of PAH.

Purpose of the Study:

  • To review the history of methamphetamine use.
  • To examine the established link between methamphetamine use and PAH.
  • To describe the clinical characteristics of patients with methamphetamine-associated PAH.

Main Methods:

  • Review of existing literature on methamphetamine use and PAH.
  • Analysis of recent cohort studies comparing methamphetamine-associated PAH with idiopathic PAH.
  • Discussion of potential mechanisms, including carboxylesterase 1 expression.

Main Results:

  • Methamphetamine-associated PAH patients exhibit poorer functional class and hemodynamics.
  • Impaired quality of life, increased healthcare utilization, and reduced survival are observed in these patients.
  • Methamphetamine-associated PAH may represent a more advanced disease state than idiopathic PAH.

Conclusions:

  • The precise mechanism linking methamphetamine use to PAH requires further investigation.
  • Methamphetamine-associated PAH patients present with a more severe disease profile.
  • Despite disease severity, methamphetamine-associated PAH is often treated less aggressively than idiopathic PAH.